MARKET

SRNE

SRNE

Sorrento Therapeutics Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

2.115
+0.105
+5.22%
Opening 13:50 07/01 EDT
OPEN
2.010
PREV CLOSE
2.010
HIGH
2.200
LOW
2.000
VOLUME
4.53M
TURNOVER
5.06M
52 WEEK HIGH
11.07
52 WEEK LOW
1.150
MARKET CAP
822.62M
P/E (TTM)
-1.3609
1D
5D
1M
3M
1Y
5Y
40 Stocks Moving In Wednesday's Mid-Day Session
 Gainers Ocean Bio-Chem, Inc. (NASDAQ: OBCI) shares jumped 116.6% to $12.82 after the company announced it will be acquired by OneWater Marine for $13.08 per share in cash.
Benzinga · 06/22 16:17
22nd Century, Wave Life top healthcare gainers; while Athira, Neptune Wellness lead losers' pack
Gainers: 22nd Century Group (XXII) +29%. Wave Life Sciences (WVE) +16%. Codex DNA (DNAY) +13%. F-star Therapeutics (FSTX) +12%. Sorrento Therapeutics (SRNE) +12%. Losers: Athira Pharma (ATHA) -70%. Neptune Wellness Solutions (NEPT) -32%. 4D pharma (LBPS) -...
Seekingalpha · 06/22 14:03
67 Biggest Movers From Yesterday
Gainers Convey Health Solutions Holdings, Inc. (NYSE: CNVY) shares jumped 138.4% to close at $10.30 as the company agreed to be taken private by TPG Capital.
Benzinga · 06/22 08:49
SRNE, ODP and MGNX among mid-day movers
Gainers: Convey Health Solutions Holdings (CNVY) +139%. Valneva (VALN) +86%. Green Giant (GGE) +78%. CEA Industries (CEAD) +76%. Clovis Oncology (CLVS) +71%. Tabula Rasa HealthCare (TRHC) +34%. Revlon (REV) +34%.
Seekingalpha · 06/21 17:07
MFGP, SRNE and OPEN among pre market losers
AC Immune ACIU -32%  as crenezumab fails in Alzheimer's study. Cango (CANG) -30%. Absci (ABSI) -14%. Hillstream BioPharma (HILS) -11%. Cepton (CPTN) -7%. Enservco Corporation (ENSV) -10%. Arcellx ACLX -10% on upsizing of follow-on
Seekingalpha · 06/16 12:35
Sorrento unit Scilex gets license to commercialize Romeg's gout treatment Gloperba
Scilex, a unit of Sorrento Therapeutics (NASDAQ:SRNE), on Tuesday said it had entered into a licensing and commercialization agreement with Romeg Therapeutics for the right to market and distribute in
Seekingalpha · 06/14 15:28
Scilex Holding Company, a Sorrento Company, enters into an agreement for an exclusive license with ROMEG Therapeutics, LLC, for the right to commercialize Gloperba®, an FDA-approved prophylactic treatment for painful gout flares in adults, in the US.
Gloperba is an FDA-approved, oral medication for treating painful gout flares in adults.Gout is a painful arthritic disorder affecting an estimated 8.7 million people in the United States1. As gout cases increase every year, treatment requirements increase...
GlobeNewswire · 06/14 14:33
Sorrento Therapeutics Licenses Gloperba Anti-Gout Medicine From RxOmeg Therapeutics
MT Newswires · 06/14 11:03
More
No Data
Learn about the latest financial forecast of SRNE. Analyze the recent business situations of Sorrento Therapeutics Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 2 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

0.00%Strong Buy
100.00%Buy
0.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average SRNE stock price target is 21.00 with a high estimate of 26.00 and a low estimate of 16.00.
High26.00
Average21.00
Low16.00
Current 2.120
EPS
Actual
Estimate
-0.46-0.34-0.23-0.11
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Institutional Holdings
Institutions: 298
Institutional Holdings: 135.61M
% Owned: 34.87%
Shares Outstanding: 388.95M
TypeInstitutionsShares
Increased
83
37.73M
New
40
4.47M
Decreased
33
1.98M
Sold Out
37
3.61M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+1.73%
Pharmaceuticals & Medical Research
+0.74%
Key Executives
Chairman/President/Chief Executive Officer/Co-Founder/Director
Henry Ji
Chief Financial Officer/Executive Vice President
Elizabeth Czerepak
Lead Director/Independent Director
Dorman Followwill
Director
Kim Janda
Director
Tammy Reilly
Director
Jaisim Shah
Independent Director
David Lemus
Independent Director
Robin Smith
Independent Director
Yue Wu
No Data
No Data
About SRNE
Sorrento Therapeutics, Inc. (Sorrento) is a clinical and commercial stage biopharmaceutical company developing new therapies to treat cancer, pain (non-opioid treatments), autoimmune disease and COVID-19. The Company's segments include Sorrento Therapeutics and Scilex. The Sorrento Therapeutics segment is organized around Immune-Oncology therapeutic area, leveraging its G-MAB antibody library and targeted delivery modalities to generate cancer therapeutics. The Scilex segment is largely organized around its non-opioid pain management operations. Sorrento's immuno-oncology platforms include key assets such as fully human antibodies (G-MAB library), immuno-cellular therapies (DAR-T), antibody-drug conjugates (ADCs), and oncolytic virus (Seprehvec). Sorrento is also developing antiviral therapies and vaccines against coronaviruses, including Abivertinib, COVI-AMG, COVISHIELD, COVI-MSC and COVIDROPS; and diagnostic test solutions, including COVITRACK and COVISTIX.

Webull offers kinds of Sorrento Therapeutics Inc stock information, including NASDAQ:SRNE real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SRNE stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading SRNE stock methods without spending real money on the virtual paper trading platform.